

L16 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1996:534956 CAPLUS
DOCUMENT NUMBER: 125:158616
TITLE: Treating disorders characterized by excessive cell proliferation with sclareolide
INVENTOR(S): Braquet, Pierre; Bigg, Denis
PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'application, Fr.
SOURCE: PCT Int. Appl., 9 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9620704	A1	19960711	WO 1996-FR15	19960104
W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2209276	AA	19960711	CA 1996-2209276	19960104
AU 9645307	A1	19960724	AU 1996-45307	19960104
EP 793492	A1	19970910	EP 1996-901018	19960104
EP 793492	B1	20030409		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE			
JP 10511673	T2	19981110	JP 1996-520787	19960104
AT 236630	E	20030415	AT 1996-901018	19960104
US 5906993	A	19990525	US 1997-875476	19970919
PRIORITY APPLN. INFO.:			GB 1995-24	A 19950104
			WO 1996-FR15	W 19960104

AB Disorders characterized by excessive cell proliferation are treated in patients by administering a therapeutically effective amt. of (+)-sclareolide. This treatment is effective against both benign hyperproliferation (e.g. fibrosis, prostatic hyperplasia, atherosclerosis, restenosis, glomerulosclerosis, keloids, psoriasis) and cancer.

IT Brain, neoplasm
Cell proliferation
Fibrosis
Keloid
Liver, neoplasm
Lung, neoplasm
Neoplasm inhibitors
Pancreas, neoplasm
Psoriasis
Skin, neoplasm
(treating disorders characterized by excessive cell proliferation with sclareolide)

L16 ANSWER 10 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2000:157430 USPATFULL
TITLE: Methods of treating microbial infection and therapeutic

formulations therefor
 INVENTOR(S): Subbiah, Ven, Edenton, NC, United States
 PATENT ASSIGNEE(S): R.J. Reynolds Tobacco Company, Winston-Salem, NC,
 United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6150381		20001121
APPLICATION INFO.:	US 1998-94058		19980609 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Davenport, Avis M.		
LEGAL REPRESENTATIVE:	Meyers Bigel Sibley & Sajovec		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
LINE COUNT:	613		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Active compounds including sclareol-like and sclareolide-like compounds are useful in methods of treating a wide variety of conditions and disorders, including those disorders caused by microbial (e.g., fungal and bacterial) infections, as well as those conditions and disorders caused by other mechanisms (e.g., activation of the adenylyl cyclase system). Pharmaceutical and cosmetic formulations comprising these active compounds are also useful in treating these disorders. One disorder that may be treated by the methods and formulations of the present invention is acne.

SUMM . . . treatment. The method comprises administering to the subject an

active compound of the present invention (i.e., a sclareol-like or a **sclareolide**-like compound), in an amount effective to treat the disorder. One embodiment of the present invention is a method of treating a **skin** condition caused by a bacterial or fungal infection in a subject in need of such treatment, comprising contacting the **skin** of the subject with an effective amount of an active compound of the present invention, including **sclareolide**, sclareol, and the cosmetically acceptable analogs and salts thereof.

The compound may be provided to the subject in a cosmetic. . . are also described herein as embodiments of the invention. Another embodiment of the invention involves a method of using a **sclareolide**-like compound to selectively activate second-messenger pathways that are involved in causing certain conditions and disorders, particularly those disorders and. . .

SUMM . . . acne excorie, gram negative acne, steroid acne, acne conglobata, or nodulocystic acne. The present invention can also be used

for **topically** treating certain types of dermatitis, e. g. perioral dermatitis, seborrheic dermatitis, gram negative folliculitis, sebaceous gland dysfunction, hidradenitis suppurativa, pseudofolliculitis. . . ringworm, athletes foot, and jock itch). The compounds are also useful in methods of preventing or ameliorating undesirable body odor. **Sclareolide**-like compounds (in particular, **sclareolide**) evaluated using the techniques described in Bencherif et al., JPET 279, 1413-1421 (1996) are determined

to exhibit a profile for. . .

CLM What is claimed is:

1. A method of treating a **skin** disorder caused by a microbial infection in a subject in need of such treatment, comprising administering a compound selected from the group consisting of sclareol and **sclareolide** to said subject in an amount effective to treat the disorder, wherein the microbe causing the microbial infection is a . . .